Skip to main content

Judd Wendell Moul, MD

James H. Semans, M.D. Distinguished Professor of Urologic Surgery, in the School of Medicine
Professor of Surgery
Professor in Anesthesiology
Office: 1573 White Zone, Duke South, Durham, NC 27710
Campus Mail: DUMC Box 3707 Med Ctr, Durham, NC 27710

Dr Judd Moul joined the Duke faculty in mid 2004 after a career in the US Army Medical Corps mainly at Walter Reed Army Medical Center.  He is a retired colonel and a noted researcher and clinician in the area of prostate cancer and is a urologic oncologist. He served as the division chief of Duke Division of Urology from 2004 to 2011 and was named the James H Semans MD Professor of surgery in 2009 becoming Duke's first named endowed chair for urology.  He was awarded the Gold Cystoscope Award from the American Urologic Association as well as Castle Connelly Physician of the year for Clinical Medicine in 2009.  He has performed more than 1300 radical prostatectomies since joining the Duke faculty and is committed to outcomes research on this series and in other areas of prostate cancer.  He served as the Editor for Prostate Cancer and Prostatic Dissease, a Nature Medicine journal, for more than a decade and is a popular speaker and lecturer having been visiting professor and keynote speaker throughout the US and the World.  He is very committed to training residents and mentoring students and trainees. 

Education and Training

  • Fellowship, Urologic Oncology, Duke University, 1988 - 1989
  • Residency, Urology, Walter Reed Army Medical Center, 1983 - 1987
  • Residency, Surgery, Walter Reed Army Medical Center, 1982 - 1983
  • M.D., Thomas Jefferson University, 1982
  • B.S., Pennsylvania State University, 1979


Azrad, M., R. T. Vollmer, J. Madden, T. J. Polascik, D. C. Snyder, M. T. Ruffin, J. W. Moul, D. Brenner, X. He, and W. Demark-Wahnefried. “Disparate results between proliferation rates of surgically excised prostate tumors and an in vitro bioassay using sera from a positive randomized controlled trial.” Biotech Histochem 90, no. 3 (April 2015): 184–89.

Full Text

Crawford, E. D., and J. W. Moul. “ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.” Oncology (Williston Park, N.Y.) 29, no. 1 (2015): 55–66.


Crawford, E David, and Judd W. Moul. “ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.” Oncology (Williston Park) 29, no. 1 (January 2015): 55–66.


Crawford, E David, Judd W. Moul, Oliver Sartor, and Neal D. Shore. “Extended release, 6-month formulations of leuprolide acetate for the treatment of advanced prostate cancer: achieving testosterone levels below 20 ng/dl.” Expert Opin Drug Metab Toxicol 11, no. 9 (2015): 1465–74.

Full Text

Moul, Judd W., Mark J. Sarno, Jonathan E. McDermed, Melissa T. Triebell, and Mark A. Reynolds. “NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy.” Urology 84, no. 6 (December 2014): 1427–32.

Full Text